✦ LIBER ✦

A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action

✍ Scribed by Brack, S.; Attinger-Toller, I.; Schade, B.; Mourlane, F.; Klupsch, K.; Woods, R.; Hachemi, H.; von der Bey, U.; Koenig-Friedrich, S.; Bertschinger, J.; Grabulovski, D.

Book ID: 126110807
Publisher: American Association for Cancer Research
Year: 2014
Tongue: English
Weight: 209 KB
Volume: 13
Category: Article
ISSN: 1535-7163
DOI: 10.1158/1535-7163.MCT-14-0046-T

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Superior Antitumor Activity of a Novel B

Superior Antitumor Activity of a Novel Bispecific Antibody Cotargeting Human Epidermal Growth Factor Receptor 2 and Type I Insulin-like Growth Factor Receptor

✍ Chen, C.; Zhang, Y.; Zhang, Y.; Li, J.; Tsao, S. W.; Zhang, M.-Y. 📂 Article 📅 2013 🏛 American Association for Cancer Research 🌐 English ⚖ 767 KB

Antitumor Activity of a Novel Bispecific

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

✍ McDonagh, C. F.; Huhalov, A.; Harms, B. D.; Adams, S.; Paragas, V.; Oyama, S.; Z 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 554 KB

Antitumor activity and mechanism of acti

Antitumor activity and mechanism of action of ultra-low dose endothelial-monocyte activating polypeptide-II combined with a tumor targeting derivative of TNF

✍ L. Crippa; A. Gasparri; A. Sacchi; E. Ferrero; F. Curnis; A. Corti 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 85 KB